Contact us

877-469-1TRM
424-208-8866

Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer

A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy, Safety, and Pharmacokinetics of Cobiprostone for the Prevention of Severe Oral Mucositis in Subjects With Head and Neck Cancer (HNC).

For more information, please visit ClinicalTrials.gov

Patient Population Investigational Product(s) Phase Status
Oral Mucositis Cobiprostone II Open and Accruing